High prevalence of target organ damage in young, African American Inner-City men with hypertension

Journal of Clinical Hypertension

Volumn 5, Issue 1, 2003, Pages 24-30

  Post, Wendy S ^a   Hill, Martha N ^b   Dennison, Cheryl R ^b   Weiss, James L ^a   Gerstenblith, Gary ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DISEASE ASSOCIATION; DRUG COST; DRUG USE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NEGRO; PREDICTION; PREVALENCE; PROTEINURIA; TARGET ORGAN; UNITED STATES; URBAN AREA;

EID: 12244253709     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.01246.x     Document Type: Article

References (37)

1. Wolz M, Cutler J, Roccella EJ, et al. Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens. 2000;13:103-104.
2. Wright JT Jr. Profile of systemic hypertension in black patients. Am J Cardiol. 1988;61:41H-45H.
3. Saunders E. Hypertension in minorities: blacks. Am J Hypertens. 1995;8:115S-119S.
4. Feldman HI, Klag MJ, Chiapella AP, et al. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397-410.
5. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1993;23:1273-1277.
6. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1999.
7. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
8. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34:973-995.
9. Obialo CI, Hewan-Lowe K. Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria. J Natl Med Assoc. 1998;90:649-655.
10. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13:I80-I93.
11. Hill MN, Bone LR, Kim MT, et al. Barriers to hypertension care and control in young urban black men. Am J Hypertens. 1999;12:951-958.
12. Casale N, Devereux RB, Alonso DR, et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565-572.
13. Rose GA, Blacburn H. Classification of the electrocardiogram for population studies. In: WHO Monograph Series #56. New York, NY: Cardiovascular Survey Methods. 1968;137-151.
14. Devereux RB, Pini R, Aurigemma GP, et al. Measurement of left ventricular mass: methodology and expertise. J Hypertens. 1997;15:801-809.
15. Reichek N, Helak J, Plappert T, et al. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation. 1983;67:348-352.
16. Collins HW, Kronenberg MW, Byrd BF III. Reproducibility of left ventricular mass measurements by two-dimensional and M-mode echocardiography. J Am Coll Cardiol. 1989;14(3):672-676.
17. De Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
18. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;59:956-960.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1993;23:1273-1277.
21. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 1986;7:639-650.
22. Devereux RB, Okin PM, Roman MJ. Pre-clinical cardiovascular disease and surrogate end-points in hypertension: does race influence target organ damage independent of blood pressure? Ethn Dis. 1998;8:138-148.
23. Coresh J, Jaar B. Further trends in the etiology of end-stage renal disease in African-Americans. Curr Opin Nephrol Hypertens. 1997;6:243-249.
24. Feldman HI, Klag MJ, Chiapella AP, et al. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397-410.
25. Daviglus ML, Liao Y, Greenland P, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA. 1999;281:530-536.
26. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
27. Matthew J, Davidson S. Narra L, et al. Etiology and characteristics of congestive heart failure in blacks. Am J Cardiol. 1996;78:1447-1450.
28. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616.
29. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension. 2000;35:6-12.
30. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277:1293-1298.
31. Feldman HI, Klag MJ, Chiapella AP, et al. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397-410.
32. Lopes AA, Hornbuckle K, James SA, et al. The joint effects of race and age on the risk of end-stage renal disease attributed to hypertension. Am J Kidney Dis. 1994;24:554-560.
33. Kailani SH, Wright JT Jr. Hypertension in African Americans: evaluation and treatment issues. J Assoc Acad Minor Phys. 1991;2:162-167.
34. Arnett DK, Hong Y, Bella JN, et al. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites. The HyperGEN Study. Am J Hypertens. 2001;14:1226-1230.
35. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 1998;32:1-9.
36. Williams DR, Rucker TD. Understanding and addressing racial disparities in health care. Health Care Financing Review. 2000;21:75-90.
37. Alderman MH. Barriers to blood pressure control. Am J Hypertens. 1999;12:1268-1269.